Inhalation therapies in acute respiratory distress syndrome

Antonio Artigas, Marta Camprubí-Rimblas, Neus Tantinyà, Josep Bringué, Raquel Guillamat-Prats, Michael A. Matthay

Research output: Contribution to journalReview articleResearchpeer-review

17 Citations (Scopus)


© Annals of Translational Medicine. The defining features of acute respiratory distress syndrome (ARDS) are an excessive inflammatory respiratory response associated with high morbidity and mortality. Treatment consists mainly of measures to avoid worsening lung injury and cannot reverse the underlying pathophysiological process. New pharmacological agents have shown promising results in preclinical studies; however, they have not been successfully translated to patients with ARDS. The lack of effective therapeutic interventions has resulted in a recent interest in strategies to prevent ARDS with treatments delivering medications directly to the lungs by inhalation and nebulization, hopefully minimizing systemic adverse events. We analyzed the effect of different aerosolized drugs such as bronchodilators, corticosteroids, pulmonary vasodilators, anticoagulants, mucolytics and surfactant. New therapeutic strategies and ongoing trials using carbon monoxide (CO) and AP301 peptide are also briefly reviewed.
Original languageEnglish
Article number293
JournalAnnals of Translational Medicine
Issue number14
Publication statusPublished - 1 Jul 2017


  • Acute lung injury (ALI)
  • Acute respiratory distress syndrome (ARDS)
  • Inhalation
  • Nebulization
  • Prevention
  • Treatment


Dive into the research topics of 'Inhalation therapies in acute respiratory distress syndrome'. Together they form a unique fingerprint.

Cite this